Real-World Perspectives in Managing CLL Treatment

Management options for chronic lymphocytic leukemia (CLL) have expanded in recent years. The emergence of new immunotherapeutic and targeted agents for both the first-line and relapsed/refractory settings"though of course beneficial for CLL patients"represents a challenge to clinicians, who must navigate the indicated uses, mechanisms of action, and toxicity profiles of these new agents. In determining optimal treatment plans, clinicians are also confronted with significant advances ...
Purdue University College of Pharmacy

Applying Guidelines and Latest Evidence to the Management of Moderate‐to‐Severe Asthma in Children and Adults

Target Audience The educational design of this activity addresses the needs of pulmonologists, allergists/immunologists, NPs and PAs, and other clinicians involved in the management of patients with moderate‐to‐severe asthma. Program Overview Patients with asthma and underlying comorbidities require personalized treatment to achieve asthma control. Children with asthma have an especially high burden of symptoms, and are at risk of impaired lung development if asthma control cannot be ...
Relias LLC

Individualized Strategies for Relapsed/Refractory Multiple Myeloma: Navigating Complexity with BCMA-Targeted and Novel Bispecific Antibodies

The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized educa...

Current and Emerging Therapies for Follicular Lymphoma: Solving Practice Challenges in Community-Based Interprofessional Care Teams

An indolent subtype of non-Hodgkin lymphoma, follicular lymphoma is characterized by eventual relapse of disease and the need for multiple lines of therapy, adding to the significant disease burden experienced by patients. Novel targeted agents in the relapsed/refractory setting have afforded new treatment options, but important clinical challenges exist, including optimal treatment sequencing, therapy evaluation and patient selection, transitions of care requirements, as well as toxicity mana...
Annenberg Center for Health Sciences

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map